MYD88 and neoplasm: However, these authors mainly focused their work on the synergy between MYD88 and the catalytic subunit HOIP which increases LUBAC ligase activity that in turns promotes NF-κB canonical activation; only four so-called CD19-cre-MYD88LP have been studied at the tumor stage.